News - Page 78 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

Post published:December 24, 2022
Post category:Press Release

Read more about the article Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Post published:December 24, 2022
Post category:Press Release

Read more about the article Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute

Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute

Post published:December 21, 2022
Post category:Press Release

Read more about the article Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022

Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022

Post published:December 21, 2022
Post category:Press Release

Read more about the article Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care

Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care

Post published:December 21, 2022
Post category:Press Release

Read more about the article Wesana Health Announces Receipt of Short-Term Loan

Wesana Health Announces Receipt of Short-Term Loan

Post published:December 21, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #127: Psilocybin Shows Promise in Bipolar Disorder; Gilgamesh Raises $39m; California Decrim. Bill Returns; Canadian Province Covers Cost of PAT

Psychedelic Bulletin #127: Psilocybin Shows Promise in Bipolar Disorder; Gilgamesh Raises $39m; California Decrim. Bill Returns; Canadian Province Covers Cost of PAT

Post published:December 19, 2022
Post category:Psychedelic Bulletin

Read more about the article The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

Post published:December 16, 2022
Post category:Press Release

Read more about the article Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

Post published:December 15, 2022
Post category:Press Release

Read more about the article FILAMENT HEALTH AND PSYENCE ANNOUNCE WORLDWIDE LICENSING AGREEMENT OF PSILOCYBIN CAPSULE FOR PALLIATIVE CARE

FILAMENT HEALTH AND PSYENCE ANNOUNCE WORLDWIDE LICENSING AGREEMENT OF PSILOCYBIN CAPSULE FOR PALLIATIVE CARE

Post published:December 15, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.